PHARMAKON ADVISORS, LP other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

04/12/2024

Adviser Type:

- Large advisory firm

Number of Employees:

12 9.09%

of those in investment advisory functions:

7 16.67%

Registration:

SEC, Approved, 3/30/2012

AUM:

3,128,821,083 8.07%

of that, discretionary:

3,128,821,083 8.07%

Private Fund GAV:

1,818,888,411 18.78%

Avg Account Size:

625,764,217 29.68%

SMA’s:

YES

Private Funds:

1 1

Contact Info

212 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
3B 2B 2B 2B 1B 827M 414M
2015 2016 2017 2018 2019 2020 2021 2022 2023

Recent News

BioDelivery Sciences International Inc.
03/29/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
03/03/2021

and/or other sources of capital to fund future development. Revenue The Company generated $15.6 million and $48.4 million of XHANCE net revenue during the three-month and twelve-month periods ...

Market Watch

Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
03/03/2021

and/or other sources of capital to fund future development. The Company generated $15.6 million and $48.4 million of XHANCE net revenue during the three-month and twelve-month periods ended ...

Yahoo Finance

Epizyme Inc (EPZM) Q4 2020 Earnings Call Transcript
02/24/2021

In addition, we raised sufficient cash to fund important growth initiatives ... a $150 million expansion of our loan facility with Pharmakon Advisors which was executed in November.

MSN


Private Funds Structure

Fund Type Count GAV
Private Equity Fund 1 $1,818,888,411

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
MONOMOY CAPITAL MANAGEMENT, L.P. - - 1.7b - - - - 1.7b 3.0b 10
MSR CAPITAL PARTNERS, LLC - - 3.3b - - - 253.6m 3.6b 3.6b 8
VMG PARTNERS II, LLC - - 3.0b - - - - 3.0b 3.0b 28
FIRST SENTIER INVESTORS 7.3b - - - - - - 7.3b 3.1b 1
SHORE CAPITAL PARTNERS - - 4.0b - - - - 4.0b 4.0b 25
BLUE WOLF CAPITAL PARTNERS LLC - - 2.8b - - - - 2.8b 2.8b 12
VESTAR CAPITAL PARTNERS, LLC - - 4.4b - - - - 4.4b 3.2b 34
MIDDLEGROUND CAPITAL - - 3.2b - - - - 3.2b 3.8b 21
ARGONAUT PRIVATE CAPITAL, LP - - 3.8b - - - - 3.8b 3.5b 8
COVE HILL PARTNERS, L.P. - - 3.1b - - - - 3.1b 3.1b 5

Private Funds



Employees




Brochure Summary

Overview

A. Pharmakon Advisors, LP (also referred to as “we”, the “Firm” and “Pharmakon”), founded in 2009, is an investment services firm specializing in investment management for private funds that are deemed to be pooled investment vehicles and their respective feeder funds (collectively the “Funds”). Pharmakon also provides certain investment advisory services to a public limited company in the UK (the “UK Trust”). Throughout this Brochure, “clients”, when used respect to the Firm, refer to the Funds and the UK Trust. The principal owners of Pharmakon are Pedro Gonzalez de Cosio and Pablo Legorreta. B. Pharmakon specializes in offering investment management services to its clients, which are comprised of the Funds and the UK Trust. In providing our advisory services to our clients, we focus on acquiring high yielding debt securities and instruments, including senior secured debt and capped return royalties with short average lives, which are securitized
or collateralized by the assets and products of life sciences companies and the royalty payments on one or more life sciences products, as applicable, which we believe will have good sales visibility during the expected life of such securities or instruments. C. Our Firm tailors our advisory services to the individual needs and specified investment mandates of our clients; however, the Firm does not tailor advisory services to the underlying individual investors in the clients. We adhere to the investment strategy set forth in our clients’ confidential private placement memoranda, investment management agreements, prospectus and other governing documents as applicable. D. We do not participate in wrap fee programs. The amount of client assets that we manage, as of December 31, 2023 is approximately $3,128,821,083, all of which are managed on a discretionary basis. We manage the Funds and the UK Trust on a discretionary basis.